Sanofi announces the signing of a share buyback mandate for up to €1 billionParis, February 3, 2026. On January 29, 2026, Sanofi announced its ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from ...

Sanofi halts plan mRNA seasonal flu vaccine, stopping phase 1 trial but continues work on mRNA pandemic flu vaccine with promising data.

Both products can be used in the UK to provide protection against RSV disease in certain settings. Abrysvo was cleared for ...

By Bhanvi Satija LONDON, Jan 29 (Reuters) - France's Sanofi, among the world's largest vaccine makers, said on Thursday that its vaccines sales would be "slightly negative" this year, partly due to U.